HIV drug development: The next 25 years

Nature Reviews Drug Discovery

Volumn 6, Issue 12, 2007, Pages 959-966

  Flexner, Charles ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALUVIA; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG CLASSIFICATION; DRUG DEVELOPMENT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG RESEARCH; DRUG STABILITY; DRUG STORAGE; DRUG TARGETING; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; PHARMACOGENOMICS; PILL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TABLET FORMULATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DRUGS, INVESTIGATIONAL; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 36749088862     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2336     Document Type: Review

References (48)

1. Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. AIDSinfo web site [online], (2006).
2. Moore, R. D., Keruly, J. C., Gebo, K. A. & Lucas, G. M. An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J. Acquir. Immune Defic. Syndr. 39, 195-198 (2005).
3. Struble, K. et al. Antiretroviral therapies fbr treatment-experienced patients: Current status and research challenges. AIDS 19, 747-756 (2005).
4. Li, F. et al. PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc. Natl Acad. Sci. USA 100, 13555-13560 (2003).
5. Markowitz, M. et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43, 509-515 (2006).
6. Cooper, D. et al. Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple class resistant virus. Abstract 105aLB. 14th Conference on Retroviruses and Opportunistic Infections web site [online], (2007).
7. Stiegbigel, R. et al. Results of BENCHMRK-2, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple class resistant virus. Abstract 105bLB. 14th Conference on Retroviruses and Opportunistic Infections web site [online], (2007).
8. Jones, G. et al. Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). Abstract 627. 14th Conference on Retroviruses and Opportunistic Infections web site [online], (2007).
9. Nelson, M. et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Auastralia, and North America: 24-week results. Abstract 104aLB. 14th Conference on Retroviruses and Opportunistic Infections web site [online], (2007).
10. Lalezari, J. et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1, 24-week results of a Phase 2b/3 study in the U. S. & Canada. Abstract 104bLB. 14th Conference on Retroviruses and Opportunistic Infections [online], (2007).
11. Gulick, R. M. et al. Phase II study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: ACTG 5211. J. Infect Dis. 196, 304-312 (2007).
12. Hendrix, C. W. et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J. Acquir. Immune Defic. Syndr. 37, 1253-1262 (2004).
13. Moyle, G. et al. CXCR4 antagonism: Proof of activity with AMD11070. Abstract 511. 14th Conference on Retroviruses and Opportunistic Infections [online], (2007).
14. Saag, M. et al. Proof of concept of ARV activity of AMD11070 (an orally administered CXCR4 entry inhibitor): Results of the first dosing cohort A studied in ACTG Protocol A5210. Abstract 512. 14th Conference on Retroviruses and Opportunistic Infections [online], (2007).
15. Stone, N. D. et al. Multiple dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects (ACTG A5191). Antimicrob. Agents Chemother. 23 Apr 2007 (doi:10.1128/AAC.00013-07).
16. Gilmour, D., Knaut, H., Maischein, H. M. & Nusslein-Volhard, C. Towing of sensory axons by their migrating target cells in vivo. Nature Neurosci. 7, 491-492 (2004).
17. Huang, Y. et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med. 2, 1240-1243 (1996).
18. Glass, W. G. et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203, 35-40 (2006).
19. Greenough, T. C., Sullivan, J. L. & Desrosiers, R. C. Declining CD4 Toell counts in a person infected with nef-deleted HIV-1. N. Engl. J. Med. 340, 236-237 (1999).
20. Haubrich, R. H. et al. A randomized trial of the activity and safety of Ro 24-7429 (tat antagonist) versus nucleoside for HIV infection. J. Infect. Dis. 172, 1246-1252 (1995).
21. Para, M. F. et al. in Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract H-256 (ASM Press, Herndon, Virginia, 2006).
22. Greene, W. C. & Peterlin, B. M. Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy. Nature Med. 8, 673-680 (2002).
23. Bishop, K. N., Holmes, R. K., Sheehy, A. M. & Malim, M. H. APOBEC-mediated editing of viral RNA. Science 305, 645 (2004).
24. Mitsuyasu, R. et al. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: A randomized controlled clinical trial - AIDS Clinical Trials Group 328. Arch. Intern. Med. 167, 597-605 (2007).
25. + lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126 946-954 (1997).
26. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. 356, 1723-1735 (2007).
27. Rowland-Jones, S.L. & Whittle, H. C. Out of Africa: What can we learn from HIV-2 about protective immunity to HIV-1? Nature Immunol. 8, 329-331 (2007).
28. Coffin, J. M. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 267, 483-489 (1995).
29. Marucco, D. A. et al. Antiretroviral activity of Pegylated interferon α-2a in patients co-infected with HIV/hepatitis C virus. J. Antimicrob. Chemother. 59, 565-568 (2007).
30. Loeb, L. A. et al. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc. Natl Acad. Sci. USA 96, 1492-1497 (1999).
31. Westby, M. et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81, 2359-2371 (2007).
32. De Gruttola, V. et al. Drug development strategies for salvage therapy: Conflicts and solutions. AIDS Res. Hum. Retroviruses 22, 1106-1109 (2006).
33. Eron, J. J. et al. Once-daily versus twice-daily lopinavir/ ritonavir in antiretroviral-naive HIV-positive patients: A 48-week randomized clinical trial. J. Infect. Dis. 189, 265-272 (2004).
34. Johnson, M. A. et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J. Acquir. Immune Defic. Syndr. 43, 153-160 (2006).
35. Martin, A. M. et al. Predisposition to abacavir hypersensitivity Conferred by HLA-B* 5701 and a haplotypic HSP70-HOM variant. Proc. Natl Acad. Sci. USA 101, 4180-4185 (2004).
36. Hetherington, S. et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122 (2002).
37. Haas, D. W. et al. Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS 18, 2391-2400 (2004).
38. Lappin, G. & Garner, R. C. Big physics, small doses: The use of AMS and PET in human microdosing of development drugs. Nature Rev. Drug Discov. 2, 233-240 (2003).
39. Lampe, F. C. et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy: A multicohort analysis, 1996 to 2002. Arch. Intern. Med. 166, 521-528 (2006).
40. Swindells, S. et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 296, 806-814 (2006).
41. Karlstrom, O., Josephson, F. & Sonnerborg, A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J. Acquir. Immune Defic. Syndr. 44, 417-422 (2007).
42. Zuger, A. Report from the XVI International AIDS Conference. ACTG 5142 compares class-sparing regimens in treatment-naive patients. AIDS Clin. Care 18, 98 (2006).
43. Zuger, A. Report from the XVI International AIDS Conference. Lopinavir/ ritonavir monotherapy. AIDS Clin. Care. 18, 99-100 (2006).
44. Muller, V. & Bonhoeffer, S. Mathematical approaches in the study of viral kinetics and drug resistance in HIV-1 infection. Curr. Drug Targets Infect. Disord. 3, 329-344 (2003).
45. McMahon, M. A. et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N. Engl. J. Med. 356, 2614-2621 (2007).
46. Gallant, J. E. et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. 354, 251-260 (2006).
47. Benson, C. A. et al. A prospective, randomized trial comparing the efficacy and safety of clarithromycin in combination with either ethambutol, rifabutin or both for the treatment of disseminated Mycobacterium ovium complex (MAC) disease in persons with AIDS. Clin. Infect. Dis. 37, 1234-1243 (2003).
48. Nettles, R. E. et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin. Infect. Dis. 42, 1189-1196 (2006).